{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=105",
    "query": {
      "condition": "Non-Small Cell Lung Cancer, Small Cell Lung Cancer",
      "page": 105
    },
    "page_size": 10
  },
  "pagination": {
    "page": 105,
    "page_size": 10,
    "total_count": 3691,
    "total_pages": 370,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=106&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=104&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T16:50:03.235Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03083808",
      "title": "Phase II Trial of Continuation Therapy in Advanced NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Greg Durm, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2017-03-20",
      "completion_date": "2022-03-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-24",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03083808"
    },
    {
      "nct_id": "NCT07327489",
      "title": "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Immunotherapy",
        "Advanced Solid Tumors Cancer",
        "Bladder Cancer",
        "TNBC, Triple Negative Breast Cancer",
        "Colorectal Cancer",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Endometrial Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Liver Cancer",
        "NSCLC (Non-small-cell Lung Cancer)",
        "Skin Cancer",
        "Melanoma (Skin Cancer)"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Elephas",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2025-04-14",
      "completion_date": "2038-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 8,
      "location_summary": "Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07327489"
    },
    {
      "nct_id": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non-small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Carcinoma",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM831",
          "type": "DRUG"
        },
        {
          "name": "NGM831 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-03-31",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 9,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05215574"
    },
    {
      "nct_id": "NCT00003497",
      "title": "Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Antineoplaston therapy (Atengenal + Astugenal)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Burzynski Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 9,
      "start_date": "1996-08-21",
      "completion_date": "1998-02-02",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003497"
    },
    {
      "nct_id": "NCT00591838",
      "title": "A Phase I/II Trial of Stereotactic Body Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Inoperable Stage I/II Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2006-09-21",
      "completion_date": "2018-06-12",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591838"
    },
    {
      "nct_id": "NCT06378658",
      "title": "A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non-small Cell Lung Cancer",
        "EGFR Mutation",
        "HER2 Mutation",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BAY2927088",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Food",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 21,
      "start_date": "2024-03-29",
      "completion_date": "2024-06-11",
      "has_results": false,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06378658"
    },
    {
      "nct_id": "NCT05526755",
      "title": "A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II-IIIB Non-small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Osimertinib 80 mg/40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 188,
      "start_date": "2023-03-06",
      "completion_date": "2029-11-22",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 3,
      "location_summary": "Santa Rosa, California • Las Vegas, Nevada • White Plains, New York",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05526755"
    },
    {
      "nct_id": "NCT01685060",
      "title": "LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "LDK378",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2012-11-26",
      "completion_date": "2016-03-29",
      "has_results": true,
      "last_update_posted_date": "2017-06-19",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 17,
      "location_summary": "Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685060"
    },
    {
      "nct_id": "NCT00372840",
      "title": "Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Malignant Mesothelioma",
        "Prostate Cancer",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Thymoma and Thymic Carcinoma"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 340,
      "start_date": "2006-05",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00372840"
    },
    {
      "nct_id": "NCT05498389",
      "title": "EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "EGFR Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "EMB-01",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2023-06",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-11-20T16:50:03.235Z",
      "location_count": 2,
      "location_summary": "Orange, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498389"
    }
  ]
}